Relay Therapeutics Prices $275M Public Offering at $12.00/Share to Fund Clinical Development

summarizeSummary

Relay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, aiming to raise approximately $258.0 million in net proceeds to fund its clinical development programs and extend its cash runway.

check_boxKey Events

• Public Offering Priced

  Relay Therapeutics priced an underwritten public offering of 22,916,667 shares of its common stock at $12.00 per share. This finalizes the terms of an offering previously announced via news on May 21, 2026.

• Significant Capital Raise

  The offering is expected to generate approximately $258.0 million in net proceeds for the company, or up to $296.8 million if the underwriters fully exercise their option to purchase an additional 3,437,500 shares.

• Share Dilution

  The offering represents approximately 12% dilution to the shares outstanding prior to this offering and is priced at a discount to the last reported sale price of $12.20 on May 15, 2026, and today's market price of $13.55.

• Funding for Clinical Development

  Proceeds will be used to fund research and clinical development of current or additional pipeline candidates, working capital, capital expenditures, and other general corporate purposes, extending the company's financial runway.

auto_awesomeAnalysis

Relay Therapeutics has finalized the terms of a significant public offering, pricing 22.9 million shares at $12.00 each. This capital raise, expected to generate approximately $258.0 million in net proceeds, is crucial for a clinical-stage biotech to fund ongoing research and development, particularly for its lead candidate zovegalisib, which recently received FDA Breakthrough Therapy designation and reported positive clinical data. While the offering is dilutive to existing shareholders, representing about 12% of pre-offering shares and priced at a discount to recent trading, it provides essential funding to extend the company's cash runway and advance its pipeline.